Cannabis Science (CBIS) 10-Q 19 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 18, 2013	Sep. 18, 2013
			Common Class A [Member]
Document Information [Line Items]	'	'	'
Entity Registrant Name	'CANNABIS SCIENCE, INC.	'	'
Entity Central Index Key	'0001024626	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Document Type	'10-Q	'	'
Document Fiscal Period Focus	'Q3	'	'
Document Period End Date	30-Sep-13	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	761,323,906	0
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash	$462	$23,560
Accounts receivable, related party	'	25,000
Prepaid expenses and deposits	'	110
Advances receivable, related party	43,062	116,943
Loans receivable, related party	41,315	22,627
Marketable securities (Note 3)	204,000	525,000
Total current assets	288,839	713,240
Computer and Equipment, net of accumulated depreciation of $10,792 and $7,327 (Note 8)	2,924	16,412
Goodwill (Note 1)	66,274	44,274
Intangibles, CCI (Note 1)	'	147,000
Intangibles, net of accumulated amortization (Note 9)	227,852	186,538
TOTAL ASSETS	585,889	1,107,464
Current Liabilities	'	'
Accounts payable	165,011	158,458
Accrued expenses, primarily management fees (Note 5)	1,310,694	1,314,050
Advances from related parties (Note 5)	239,344	196,703
Management bonuses	300,000	300,000
Notes payable to stockholders (Note 6)	1,539,502	1,307,218
TOTAL CURRENT LIABILITIES	3,554,551	3,276,429
Stockholders' Deficit	'	'
Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at September 30, 2013 and 666,666 at December 31, 2012	1,000	667
Common stock value	710,824	663,791
Prepaid consulting	2,886,330	2,864,070
Additional paid-in capital	89,673,024	86,604,888
Accumulated deficit	-90,467,180	-86,574,241
Total stockholders' deficit	-2,968,662	-2,168,965
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	585,889	1,107,464
Common Class A [Member]	'	'
Stockholders' Deficit	'	'
Common stock value	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Computer and Equipment, net of accumulated depreciation	$10,792	$7,327
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	666,666
Preferred stock, shares outstanding	1,000,000	666,666
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	850,000,000	850,000,000
Common stock, shares issued	710,823,906	663,790,573
Common stock, shares outstanding	710,823,906	663,790,573
Common Class A [Member]	'	'
Common stock, par value	$0.00	$0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Revenue	$70,581	$1,848	$72,185	$33,568
Operating Expenses	'	'	'	'
Investor relations	'	20,980	3,601	105,486
Professional fees	12,109	14,461	83,695	248,310
Net loss on disposal of assets	'	'	8,896	'
Net loss (gain) on settlement of liabilities	582,000	1,530,000	1,674,150	10,826,800
Depreciation and Amortization	21,143	19,242	88,278	30,116
General and administrative	529,902	487,831	1,821,991	2,948,973
Total operating expenses	1,145,154	2,072,514	3,680,611	14,159,685
Net Operating Profit (Loss)	-1,074,573	-2,070,666	-3,608,426	-14,126,117
Other income (expense)	'	'	'	'
Interest income, net	6	750	7	1,500
Interest expense, net	-220	-8,128	-977	-9,039
Gain on sale of JV assets	'	'	262,250	'
Gain on debt settlements	'	2,283	37,458	38,252
Unrealized gain (loss) on marketable securities	-111,000	'	-583,250	'
Net Income (Loss) Before Income Taxes	-1,185,787	-2,075,761	-3,892,939	-14,095,404
State income taxes paid	'	'	'	800
Income tax provision	'	'	'	'
Income tax benefit	'	'	'	'
Net tax	'	'	'	800
Net Loss	($1,185,787)	($2,075,761)	($3,892,939)	($14,096,204)
Net loss per common share - Basic and diluted	$0	$0	($0.01)	($0.03)
Weighted average number of common shares outstanding	706,560,863	676,616,769	690,252,600	554,242,735

Consolidated_Statement_Of_Stoc

Consolidated Statement Of Stockholders Equity (Deficit) (USD $)	Common Stock	Preferred Stock	Additional Paid-In Capital	Prepaid Consulting	Accumulated Deficit	Total
Balance Amount at Dec. 31, 2011	$305,421	$1,000	$68,379,003	($379,156)	($70,536,669)	($2,230,401)
Balance Shares at Dec. 31, 2011	305,420,574	999,999	'	'	'	'
Common stock issued for services, Shares	171,669,999	'	'	'	'	'
Common stock issued for services, Amount	171,670	'	5,965,555	-4,989,800	'	1,147,425
Common stock issued for debt settlements, Shares	155,700,000	'	'	'	'	'
Common stock issued for debt settlements, Amount	155,700	'	10,688,100	'	'	10,843,800
Common stock issued for assets and acquisitions, Shares	22,750,000	'	'	'	'	'
Common stock issued for assets and acquisitions, Amount	22,750	'	750,680	'	'	773,430
Common stock issued in connection with joint ventures, Shares	7,000,000	'	'	'	'	'
Common stock issued in connection with joint ventures, Amount	7,000	'	331,800	'	'	338,800
Common stock pending issuance for services, Shares	7,000,000	'	'	'	'	'
Common stock pending issuance for services, Amount	7,000	'	434,000	'	'	441,000
Common stock pending cancellation for services, Shares	-750,000	'	'	'	'	'
Common stock pending cancellation for services, Amount	-750	'	750	'	'	'
Common stock pending cancellation for acquisition, Shares	-5,000,000	'	'	'	'	'
Common stock pending cancellation for acquisition, Amount	-5,000	'	5,000	'	'	'
Amortization of shares issued for services	'	'	'	2,504,886	'	2,504,886
Forfeiture of Series A Preferred stock, Shares	'	-333,333	'	'	'	'
Forfeiture of Series A Preferred stock, Amount	'	-333	'	'	'	-333
Stockholder gift to settle liability	'	'	50,000	'	'	50,000
Net Loss	'	'	'	'	-16,037,572	-16,037,572
Balance Amount at Dec. 31, 2012	663,791	667	86,604,888	-2,864,070	-86,574,241	-2,168,965
Balance Shares at Dec. 31, 2012	663,790,573	666,666	'	'	'	663,790,573
Common stock issued for services, Shares	17,700,000	'	'	'	'	'
Common stock issued for services, Amount	17,700	'	870,150	-490,000	'	397,850
Common stock issued for debt settlements, Shares	28,500,000	'	'	'	'	'
Common stock issued for debt settlements, Amount	28,500	'	1,674,150	'	'	1,702,650
Common stock issued for assets and acquisitions, Amount	'	'	'	'	'	'
Amortization of shares issued for services	'	'	'	'	967,742	967,742
Common stock issued for private placement, Shares	833,333	'	'	'	'	'
Common stock issued for private placement, Amount	833	'	24,167	'	'	25,000
Preferred stock issued for services, Shares	'	333,334	'	'	'	'
Preferred stock issued for services, Amount	'	333	499,669	-500,002	'	'
Net Loss	'	'	'	'	-3,892,939	-3,892,939
Balance Amount at Sep. 30, 2013	$710,824	$1,000	$89,673,024	($2,886,330)	($90,467,180)	($2,968,662)
Balance Shares at Sep. 30, 2013	710,823,906	1,000,000	'	'	'	710,823,906

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Statement of Cash Flows [Abstract]	'	'
Net income (loss)	($3,892,939)	($14,096,204)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	4,592	755
Amortization	83,686	29,281
Debt issued for payment of expenses	'	85,633
Stock issued for services	1,365,592	2,405,919
Gain on joint ventures	-262,250	'
Loss on marketable securities	583,250	'
Loss on settlement of debt	-1,674,150	-10,826,800
Impairment loss on goodwill	8,896	'
Accounts receivable	'	'
Accounts receivable, related parties	25,000	-99,655
Prepaid expenses and deposits	110	-2,316
Inventory	'	-60,258
Accounts payable	110,383	187,573
Accrued expenses, including management fees	-3,356	173,847
NET CASH (USED) IN OPERATING ACTIVITIES	-302,886	-548,625
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Net liabilities acquired in GGECO	'	-25,861
Purchase of website	'	-2,160
Loans receivable, related parties	-30,652	-21,054
Advances receivable, related parties	-14,155	'
Repayment from advances receivable, related parties	25,000	'
Purchase of property, plant & equipment	'	-7,440
CASH FLOWS USED IN INVESTING ACTIVITIES	-19,807	-56,515
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Repayment of convertible note-stockholder	155	'
Proceeds from advances from officer	'	9,000
Repayments on advances from officer	-1,702	-7,000
Proceeds from notes payable-stockholders	204,000	609,435
Repayments on advances from related parties	72,452	1,000
Proceeds from sale of common stock	25,000	'
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES	299,595	612,435
NET INCREASE (DECREASE) IN CASH	-23,098	7,295
CASH, BEGINNING OF PERIOD	23,560	2,197
CASH, END OF PERIOD	462	9,492
Common stock issued for services	1,387,519	6,542,325
Common stock issued for settlement of debt	1,702,650	10,975,000
Debt converted into common stock	28,500	148,200
Common stock issued for assets	'	1,082,000
Common stock issued for products	'	260,000
Cancellation of shares issued for services	'	103,500
Preferred stock issued for services	500,002	'
Marketable securities acquired through sale of JV	262,250	'
Acquisition payment paid through note payable, related party	'	155,000
Accounts payable paid through note payable, stockholder	82,308	163,332
Advance from related party paid to AGI (Note 4)	'	25,000
Accounts payable paid by related parties	21,891	13,884
Accounts payable paid through stockholder gift	'	50,000
Intangibles, CCI allocated to goodwill	22,000	'
Intangibles, CCI allocated to intangibles	125,000	'
Accounts and advances receivable, related party, repaid by payment to advances from related party	50,000	'
Advances to related party paid by payment to notes payable stockholders	$25,000	'

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	1. SUMMARY OF SIGNIFICICANT ACCOUNTING POLICIES
	A. Organization and General Description of Business
	Cannabis Science, Inc.  (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc.  On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation.  On March 25, 2008 the Company changed its name to Gulf Onshore, Inc.  On April 7, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.
	On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS.
	Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
	B.  Basis of Presentation
	These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars.  The Company’s fiscal year end is December 31.
	Interim Financial Reporting
	While the information presented in the accompanying interim financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP").  These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2012 audited financial statements of Cannabis Science, Inc. (the “Company”).  All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the nine month periods ended September 30, 2013 and 2012.  It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2012 included in our Form 10-K, filed with the Securities Exchange Commission on April 23, 2013. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that can be expected for the year ending December 31, 2013.
	The operating results of GGECO University, Inc. (“GGECO”), acquired on February 9, 2012, for the period February 10, 2012 through December 31, 2012 were consolidated with the consolidated financial statements of the Company for the year ended December 31, 2012. The s-type corporation of GGECO was dissolved in 2012 and all operations combined into the Company’s. An independent valuation firm determined the intangibles acquired in GGECO to be $192,119 consisting of $150,000 for educational materials, $20,000 for the trade name, and $22,119 for the workforce. The total purchase price of $450,132, including acquired net liabilities, audit and valuation costs was recorded. A total of $44,274 in unimpaired goodwill remains at September 30, 2013.
	The operating results of Cannabis Consulting, Inc. (“CCI”), acquired on March 21, 2012, for the period March 21, 2012 through December 31, 2012 and January 1, 2013 through September 30, 2013 were consolidated with the consolidated financial statements of the Company for the three months ended September 30, 2013. The s-type corporation of CCI was dissolved in 2012 and all operations combined into the Company’s. The Company has allocated $125,000 of the purchase price to intangibles based on an internal valuation in addition to $22,000 of goodwill. No impairment in the fair market value of CCI was determined at September 30, 2013.
	On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. No business or operating activities have commenced in the subsidiaries as of September 30, 2013.
	C. Use of Estimates
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
	D. Basic and Diluted Net Income (Loss) Per Share
	Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share.  Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.  For the three and nine months ended September 30, 2013 and September 30, 2012, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
	E. Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
	F. Long-Lived Assets & Impairment on Oil Lease Investments
	Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.
	G. Inventory
	Inventories are stated at the lower of cost or market, using the average cost method. Cost includes materials related to the purchase and production of inventories. We regularly review inventory quantities on hand, future purchase commitments with our suppliers, and the estimated utility of our inventory. If our review indicates a reduction in utility below carrying value, we reduce our inventory to a new cost basis through a charge to cost of revenue.
	H. Fair Value Measurements
	Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.
	In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.
	I. Technology License and Royalties
	The Company's former principal business activity focused on oil and gas exploration. We have divested ourselves of all oil and gas properties and are investigating other business opportunities. We have no technology licenses or rights to any royalties for formerly owned oil and gas properties.
	J. Goodwill and Intangible Assets
	Under ASC Topic 350 “Intangibles-Goodwill and Other”, Intangible assets and goodwill, if any, will be calculated and allocated from intangibles designated in the acquisitions of GGECO, and CCI, pursuant to a valuation by an accredited independent certified business valuator and/or internal valuation, where acquisitions were immaterial in nature. Finite life intangibles will be tested for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. A preliminary allocation of all acquisition costs has been made to intangible assets under the aforementioned acquisitions.
	The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).
	The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.
	The Company determined and recorded an impairment loss on goodwill of $405,858 which was included in operating expenses and resulting net operating loss for the year ended December 31, 2012.
	K. Research and Development Expenses
	Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
	L. Income Taxes
	Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.
	Unfiled Federal Tax Returns
	In February 2009, the Company filed appropriate federal tax returns for the years ending December 31, 2003 through 2007 and may be subject to failure to file penalties. For the years ending December 31, 2008 through December 31, 2012, the Company has not filed any federal tax returns. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.
	M. Marketable Securities
	Under ASC Topic 210; Rule 5-02.2, ‘‘Marketable Securities’’, the Company is required to measure all marketable securities at their carrying value while recognizing unrealized gains and losses as of the reporting date.
	N. Stock-Based Compensation
	Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) as of January 1, 2006 and recognizes stock-based compensation expense using the modified prospective method.
	O. Revenue Recognition
	Revenue is recognized at the time the educational materials or online seminars are provided and billed to the customer and collection of such fee is reasonably assured. License fees and joint-venture profit sharing when evidenced by executed agreements, and other fees are recognized when earned and collection is reasonably assured.
	P. Basic and Diluted Net Earnings (loss) per Share
	Under ASC Topic 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the nine months ended September 30, 2013 and September 30, 2012, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
	Q. Development Stage Enterprise
	The Company is no longer in the development stage. The Company is actively working on formulations for cannabinoid-based drug development, filing INDs, and commencing drug trials for FDA approved medicine. The Company’s businesses of GGECO and CCI acquired during 2012 are continuing and the Company’s other activities under license agreements with Apothecary has completed over a year of active business and development with expanding operations along with associated business of which the Company earned $70,000 in royalty license revenues in Q3 of 2013 and expects increased revenues in Q4 of 2013. The Company’s MOU with Prescription Vending Machines is progressing with new consultants engaged in Q4 of 2013 to work towards commencing operations in Canada. Therefore, the Company has transitioned out of the development stage as defined under the provisions of ASC Topic 915-10 in the quarter ended September 30, 2013.
	R. Recent Accounting Pronouncements
	During the nine months ended September 30, 2013 and through November 18, 2013, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.
	S. Reclassifications
	For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

Going_Concern

Going Concern	9 Months Ended
	Sep. 30, 2013
Going Concern	'
GOING CONCERN	'
	2. GOING CONCERN
	The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company reported an accumulated deficit of $90,467,180 and had a stockholders’ deficit of $2,968,662 at September 30, 2013.
	In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital. At September 30, 2013, the Company had minimal operations. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	We anticipate that we will have to raise additional capital to fund operations over the next 12 months. To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities. There are no commitments or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to the terms of any such financings. Any future financing may involve substantial dilution to existing investors. We had been relying on our common stock to pay third parties for services which has resulted substantial dilution to existing investors.

Marketable_Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2013
Investments, Debt and Equity Securities [Abstract]	'
MARKETABLE SECURITIES	'
	3. MARKETABLE SECURITIES
	At September 30, 2013, the Company held 7,500,000 common shares in the Endocan Corporation (formerly X-Change Corporation) (OTCBB: ENDO) (“Endocan”) representing approximately 8.6% of the issued and outstanding shares of X-Change, of which 5,000,000 common shares were acquired at a fair market value of $150,000 or $0.03 on December 12, 2012 and 2,500,000 common shares were acquired at a fair market value of $262,250 or $0.1049 per share on February 8, 2013. The 5,000,000 common shares were received as consideration for the sale of its rights and interest in the dupetit Natural Products GmbH joint-venture operating agreement to Endocan under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the sale of its rights and interest in the Maliseet joint-venture operating agreement to Endocan under an Asset Purchase Agreement. The value of the shares at September 30, 2013 was determined to be $0.0272 per share or $204,000 with the Company recording an unrealized loss of $111,000 and $583,250 for the three and nine months ended September 30, 2013, respectively.

Fair_Value_Measurements_and_Di

Fair Value Measurements and Disclosures	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE MEASUREMENTS AND DISCLOSURES	'
	4. FAIR VALUE MEASUREMENTS AND DISCLOSURES
	ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC Topic 820 are described as follows:
	Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability to access.
	Level 2 Inputs to the valuation methodology include:
		-	quoted prices for similar assets or liabilities in active markets;
		-	quoted prices for identical or similar assets or liabilities in inactive markets;
		-	inputs other than quoted prices that are observable for the asset or liability;
		-	inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.
	Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
	The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.
	Following is a description of the valuation methodologies used for the Company’s liabilities measured at fair value. There have been no changes in the methodologies used at September 30, 2013.
	Investment in marketable securities: Trading securities valued at the closing price of XCHC shares held by the Company at period end.
	Intangibles from GGECO and CCI acquisitions: Valued at replacement cost. The replacement cost is determined as the cost of replacing the asset with a modern unit of the near equivalent utility.
	The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The following tables set forth by level, within the fair value hierarchy, the Company’s liabilities at fair value as of September 30, 2013.
	31-Dec-12
			Level 1		Level 2		Level 3		Total
	Investment in trading securities		$	525,000	$	—	$	—	$	525,000
	Intangibles from acquisitions, GGECO and CCI
	net of accumulated amortization			—		—		157,918		157,918
	Total assets as of December 31, 2012		$	525,000	$	—	$	157,918	$	682,918
	30-Sep-13
				Level 1		Level 2		Level 3		Total
	Investment in trading securities		$	204,000	$	—	$	—	$	204,000
	Intangibles from GGECO and CCI acquisitions,
	net of accumulated amortization			—		—		237,480		237,480
	Total assets as of September 30, 2013		$	204,000	$	—	$	237,480	$	441,480

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	5. RELATED PARTY TRANSACTIONS
	At September 30, 2013, a total of $233,178 (December 31, 2012: $196,703) in loans payable was due to Bogat Family Trust, Raymond Dabney the Company’s Managing Consultant as trustee, and a $6,166 to Raymond Dabney (December 31, 2012: $0). The loan amounts due are non-interest bearing, unsecured and have no specified terms of repayment. Raymond Dabney also performs management services to the Company under a Management Consulting Agreement signed on February 9, 2012.
	On January 1, 2013, the Company entered into five year Management Agreements and issued 166,667 Series A preferred shares each to Robert J. Melamede, President/interim CFO and Bogat Family Trust, Raymond Dabney trustee, for services rendered.
	On February 8, 2013, the Company sold its rights and interest in the Maliseet Nation at Tobique Joint Venture to the Endocan for consideration of 2,500,000 common shares with a fair market value or $0.1049 per share or $262,250. Dr. Dorothy Bray, CEO and director is also President and director of Endocan, Robert Kane, V.P. of Investor Relations is the CFO and a director of Endocan and Mr. Kane was appointed CFO and Director of Cannabis Science, Inc. on November 13, 2013. Chad S. Johnson, Esq., COO, general counsel and a director is also a director and general counsel for Endocan. The Company recorded an unrealized loss on marketable securities of $194,250 for the nine months ended September 30, 2013, respectively, in regards to the Endocan shares received under this transaction.
	For the nine months ended September 30, 2013, the following related party stock-based compensation was recorded:
	Related Party		Position	Amount
	Dr. Dorothy Bray		CEO	$	42,311
	Dr. Robert Malemede		President, CFO		207,186
	Dr. Richard Ogden		CSO		59,415
	Bogat Family Trust1		Managing Consultant		25,000
	Raymond Dabney		Managing Consultant		207,186
	Chad S. Johnson, Esq.		COO and General Counsel		367,500
	Mario Lap		Director		25,525
				$	934,123
	1Raymond Dabney, managing consultant is acting trustee of Bogat Family Trust.
	During the nine months ended September 30, 2013, a stockholder of the Company, Intrinsic Venture Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Note Amount			Issue Date
	$	20,000		January 2, 2013 (non-cash)
	$	5,000		4-Jan-13
	$	15,000		16-Jan-13
	$	22,000		4-Feb-13
	$	11,000		7-Feb-13
	$	25,000		28-Feb-13
	$	20,000		8-Mar-13
	$	30,500		1-Apr-13
	$	2,500		17-May-13
	$	2,500		30-Aug-13
	$	22,000		13-Sep-13
	Total loans under notes payable were $175,500 for the nine months ended September 30, 2013.
	During the nine months ended September 30, 2013, a stockholder of the Company, Intrinsic Capital Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Note Amount			Issue Date
	$	22,000		17-May-13
	$	15,000		31-May-13
	$	10,229		3-Jul-13
	$	38,328		23-Jul-13
	$	1,250		15-Aug-13
	$	1,250		30-Aug-13
	$	10,000		9-Sep-13
	$	14,000		11-Sep-13
	$	1,250		30-Sep-13
	Total loans under notes payable were $113,308 for the nine months ended September 30, 2013.

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
NOTES PAYABLE	'
	6. NOTES PAYABLE
	As at September 30, 2013, a total of $1,539,502 (December 31, 2012: $1,307,218) of notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on October 1, 2013 through September 30, 2014. A stockholder, to whom $1,451,194 in promissory notes are due, also performs business and accounting services for the Company on a month-to-month basis. A total of $113,308 (December 31, 2012: $0) is due to a stockholder under promissory notes that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on May 17 through September 30, 2014.

Equity_Transactions

Equity Transactions	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
EQUITY TRANSACTIONS	'
	7.  EQUITY TRANSACTIONS
	The Company is authorized to issue 850,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 710,423,906 issued and outstanding as of September 30, 2013.
	The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $0.001 per share. These shares have 10 votes per share. There were 0 issued and outstanding as of September 30, 2013.
	The Company is also authorized to issue 1,000,000 shares of preferred stock. These shares have full voting rights of 1,000 votes per share. There were 1,000,000 issued and outstanding as of September 30, 2013.
	On February 9, 2012, the Company established a 2012 Equity Compensation Plan that authorizes the Company to issue up to 50,000,000 common shares to staff or consultants for services to or on behalf of the Company. The Company filed a Registration Statement Form S-8 with the U.S. Securities and Exchange Commission on February 14, 2012, file no. 333-179501, to register the shares covered under the plan. As of September 30, 2013, the Company has issued 3,000,000 common shares compensation under the plan that were issued on February 24, 2012 to Vincent Mehdizadeh with a fair market value of $0.02 or $246,000 for services rendered under a Consulting Agreement.
	During the nine months ended September 30, 2013, the Company issued the following common stock:
	On January 29, 2013, the Company issued 5,000,000 common shares with a fair market value of $250,000 to Chad S. Johnson, Esq. due under a January 1, 2013 bonus agreement for services in the capacity of COO.
	On February 11, 2013, the Company issued 1,000,000 common shares, with a fair market value of $71,500 or $0.0715 per share, to a scientific advisor for services rendered under a management agreement.
	On February 28, 2013, the Company issued 13,500,000 common shares for settlement of $13,500 of stockholder debt, for a loss on settlement of $1,092,150, assigned from the stockholder notes payable originating on July 1, 2011 and July 11, 2011.
	On March 7, 2013, the Company issued 500,000 common shares, with a fair market value of $35,750 or $0.0715 per share, to a scientific advisor for services rendered under a two-year management agreement.
	On March 26, 2013, the Company effectively issued 100,000 common shares at a fair market value of $0.0775 for services rendered under a February 26, 2013 management agreement with Dr. Richard Ogden, CSO of the Company.
	On March 28, 2013, the Company issued 500,000 common shares with a fair market value of $38,750, or $0.715 per share, to a scientific advisor pursuant to a February 26, 2013 management agreement.
	On April 12, 2013, the Company retroactively cancelled 41,750,000 common shares as if they had never been issued previously to Dr. Mohammad Afaneh pursuant to his termination in Q4 and a court approved settlement in February 2013. All transactions pertaining to these shares issued to Dr. Afaneh were reversed as if they have never occurred in these consolidated financial statements for the year ended December 31, 2012.
	On April 26, 2013, the Company effectively issued 100,000 common shares at a fair market value of $0.066 for services rendered under a February 26, 2013 management agreement with Dr. Richard Ogden, CSO of the Company.
	On May 20, 2013, the Company issued 5,000,000 common shares with a fair market value of $230,500 to the newly appointed CEO and director, Dr. Dorothy Bray, for services rendered under a two-year management agreement.
	On May 26, 2013, the Company effectively issued 100,000 common shares at a fair market value of $0.0553 for services rendered under a February 26, 2013 management agreement with Dr. Richard Ogden, CSO of the Company.
	On June 7, 2013, the Company issued 833,333 common shares at $0.03 per share to an accredited investor under a private placement subscription for total proceeds of $25,000.
	On June 24, 2013, the Company issued 5,000,000 common shares with a fair market value of $185,000 to the newly appointed director and director and officer of European subsidiaries, Mario Lap, for services rendered under a two-year management agreement.
	On July 1, 2013, the Company effectively issued 100,000 common shares at a fair market value of $0.0387 for services rendered under a February 26, 2013 management agreement with Dr. Richard Ogden, CSO of the Company.
	On July 25, 2013, the Company issued 15,000,000 common shares for settlement of $15,000 of stockholder debt, for a loss on settlement of $582,000, assigned from the stockholder notes payable originating on December 31, 2011.
	On July 26, 2013, the Company effectively issued 100,000 common shares at a fair market value of $0.0398 for services rendered under a February 26, 2013 management agreement with Dr. Richard Ogden, CSO of the Company.
	On August 26, 2013, the Company effectively issued 100,000 common shares at a fair market value of $0.041 for services rendered under a February 26, 2013 management agreement with Dr. Richard Ogden, CSO of the Company.
	On September 26, 2013, the Company effectively issued 100,000 common shares at a fair market value of $0.0452 for services rendered under a February 26, 2013 management agreement with Dr. Richard Ogden, CSO of the Company.
	Stock Options:
	The following options were issued to the Company’s V.P of investor relations, CFO and Director for services rendered under a September 16, 2011 agreement:
		(i)	the option to purchase 100,000 common shares at ten cents ($0.10) per share;
		(ii)	the option to purchase 100,000 common shares at ten cents ($0.20) per share;
		(iii)	the option to purchase 500,000 common shares at ten cents ($0.35) per share; and
		(iv)	the option to purchase 1,000,000 common shares at ten cents ($0.10) per share.
	A summary of the status of the Company’s option grants as of September 30, 2013 and the changes during the period then ended is presented below:
					Shares		Weighted-Average
							Exercise Price
		Outstanding December 31, 2012				1,700,000	$	0.41
		Granted				—		—
		Exercised				—		—
		Expired				—		—
		Outstanding September 30, 2013				1,700,000	$	0.41
		Options exercisable at September 30, 2013				—		—
	These options expire on the date of termination of the management agreement and services thereunder with Robert Kane. The weighted average fair value at date of grant for options during nine months ended September 30, 2013 was estimated using the Black-Scholes option valuation model with the following:
	Average expected life in years			2
	Average risk-free interest rate			2	%
	Average volatility			75	%
	Dividend yield			0	%

Equipment

Equipment	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
EQUIPMENT	'
	8. EQUIPMENT
				Accumulated		Net Book Value		Net Book Value
		Cost		Depreciation		30-Sep-13		31-Dec-12
	Equipment	$	3,000	$	3,000	$	—	$	367
	Laboratory equipment		—		—		—		8,895
	Software		5,000		2,859		2,141		4,017
	Computers		5,716		4,933		783		3,133
			13,716		10,792		2,924		16,412
	All equipment is stated at cost.  Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized.  Depreciation is computed using the straight-line method over the estimated lives of the related assets, 2 years for computer, 2 years for software, and 5 years for equipment and laboratory equipment.

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	9. INTANGIBLE ASSETS
		30-Sep-13			31-Dec-12
	Intellectual assets, primarily intellectual property	$	445,299		$	320,299
	Less accumulated amortization		(217,447	)		(133,761	)
		$	227,852		$	186,538
	Intangible assets are stated at fair value on the date of purchase less accumulated amortization. Amortization is computed using the straight-line method over the estimated lives of the related assets (5 years for intellectual assets).

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	10. SUBSEQUENT EVENTS
	On Intrinsic Venture Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Amount	Date
	$2,500	1-Oct-13
	$1,275	16-Oct-13
	Intrinsic Capital Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Amount	Date
	$2,500	1-Oct-13
	$2,750	22-Oct-13
	Total promissory note loans were $9,025 to the Company for the period subsequent to the nine months ended September 30, 2013 to November 18, 2013.
	On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.
	Subsequent to the nine months ended September 30, 2013, the Company issued the following stock for the settlement of debt and for services:
	On October 21, 2013, the Company issued bonuses of 5,000,000 shares of common stock with a fair market value of $190,000 or $0.03 per share to each of Dorothy Bray, CEO, Mario Lap, Director of European operations and subsidiaries, and Chad S. Johnson, Esq., Director and General Counsel.
	On November 5, 2013, the Company issued 5,000,000 shares of common stock with a fair market value of $170,000 or $0.034 per share to each of two consultants for services rendered for business development in Canada under two year consulting agreements.
	On November 5, 2013, the Company issued 9,000,000 common shares for settlement of $9,000 of stockholder debt, for a loss on settlement of $297,000, assigned from the stockholder notes payable originating on January 27, 2012.
	On November 6, 2013, the Company issued 9,000,000 common shares for settlement of $9,000 of stockholder debt, for a loss on settlement of $283,500, assigned from the stockholder notes payable originating on January 27, 2012.
	On November 18, the Company issued 1,500,000 shares of common stock with a fair market value of $52,500 or $0.034 per share pursuant to a November 14, 2013 two-year management agreement to Robert Kane for CFO and Director services to the Company.
	On November 18, 2013, the Company issued 1,000,000 shares of common stock with a fair market value of $37,000 or $0.037 per shares pursuant to a November 12, 2013 one-year consulting agreement to a consultant for research and development services.
	Common shares reconciliation table:
	Issued and outstanding as of September 30, 2013…	710,823,906
	Pending and subsequent event issuances…	50,500,000
	Unissued and outstanding as of November 18, 2013…	761,323,906

Recovered_Sheet1

Summary Of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Summary Of Significant Accounting Policies Policies	'
Organization and General Description of Business	'
	A. Organization and General Description of Business
	Cannabis Science, Inc.  (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc.  On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation.  On March 25, 2008 the Company changed its name to Gulf Onshore, Inc.  On April 7, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.
	On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS.
	Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Basis of Presentation	'
	B.  Basis of Presentation
	These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars.  The Company’s fiscal year end is December 31.
	Interim Financial Reporting
	While the information presented in the accompanying interim financial statements is unaudited, it includes all adjustments, which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with generally accepted accounting principles in the United States of America ("GAAP").  These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2012 audited financial statements of Cannabis Science, Inc. (the “Company”).  All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the nine month periods ended September 30, 2013 and 2012.  It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2012 included in our Form 10-K, filed with the Securities Exchange Commission on April 23, 2013. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that can be expected for the year ending December 31, 2013.
	The operating results of GGECO University, Inc. (“GGECO”), acquired on February 9, 2012, for the period February 10, 2012 through December 31, 2012 were consolidated with the consolidated financial statements of the Company for the year ended December 31, 2012. The s-type corporation of GGECO was dissolved in 2012 and all operations combined into the Company’s. An independent valuation firm determined the intangibles acquired in GGECO to be $192,119 consisting of $150,000 for educational materials, $20,000 for the trade name, and $22,119 for the workforce. The total purchase price of $450,132, including acquired net liabilities, audit and valuation costs was recorded. A total of $44,274 in unimpaired goodwill remains at September 30, 2013.
	The operating results of Cannabis Consulting, Inc. (“CCI”), acquired on March 21, 2012, for the period March 21, 2012 through December 31, 2012 and January 1, 2013 through September 30, 2013 were consolidated with the consolidated financial statements of the Company for the three months ended September 30, 2013. The s-type corporation of CCI was dissolved in 2012 and all operations combined into the Company’s. The Company has allocated $125,000 of the purchase price to intangibles based on an internal valuation in addition to $22,000 of goodwill. No impairment in the fair market value of CCI was determined at September 30, 2013.
	On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. No business or operating activities have commenced in the subsidiaries as of September 30, 2013.
Use of Estimates	'
	C. Use of Estimates
	The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
Basic and Diluted Net Income (Loss) Per Share	'
	D. Basic and Diluted Net Income (Loss) Per Share
	Under ASC 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share.  Basic EPS includes no dilution and is computed by dividing income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.  Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity.  For the three and nine months ended September 30, 2013 and September 30, 2012, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
Cash and Cash Equivalents	'
	E. Cash and Cash Equivalents
	The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Long-Lived Assets & Impairment on Oil Lease Investments	'
	F. Long-Lived Assets & Impairment on Oil Lease Investments
	Under ASC Topic 360, “Property, Plant, and Equipment”, the Company is required to periodically evaluate the carrying value of long-lived assets to be held and used. ASC Topic 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost of disposal.
Inventory	'
	G. Inventory
	Inventories are stated at the lower of cost or market, using the average cost method. Cost includes materials related to the purchase and production of inventories. We regularly review inventory quantities on hand, future purchase commitments with our suppliers, and the estimated utility of our inventory. If our review indicates a reduction in utility below carrying value, we reduce our inventory to a new cost basis through a charge to cost of revenue.
Fair Value Measurements	'
	H. Fair Value Measurements
	Under ASC Topic 820, the Company discloses the estimated fair values of financial instruments. The carrying amounts reported in the balance sheet for current assets and current liabilities qualifying as financial instruments are a reasonable estimate of fair value.
	In accordance with the reporting requirements of ASC Topic 825, Financial Instruments, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the consolidated financial statements when the fair value is different than the carrying value of those financial instruments (see Note 4). The estimated fair value of other current assets and current liabilities approximate their carrying amounts due to the relatively short maturity of these instruments. None of these instruments are held for trading purposes.
Technology License and Royalties	'
	I. Technology License and Royalties
	The Company's former principal business activity focused on oil and gas exploration. We have divested ourselves of all oil and gas properties and are investigating other business opportunities. We have no technology licenses or rights to any royalties for formerly owned oil and gas properties.
Goodwill and Intangible Assets	'
	J. Goodwill and Intangible Assets
	Under ASC Topic 350 “Intangibles-Goodwill and Other”, Intangible assets and goodwill, if any, will be calculated and allocated from intangibles designated in the acquisitions of GGECO, and CCI, pursuant to a valuation by an accredited independent certified business valuator and/or internal valuation, where acquisitions were immaterial in nature. Finite life intangibles will be tested for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. A preliminary allocation of all acquisition costs has been made to intangible assets under the aforementioned acquisitions.
	The Company tests the carrying value of goodwill and indefinite life intangible assets for impairment at least once a year and more frequently if an event or circumstance indicates the asset may be impaired. An impairment loss is recognized if the amount of the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less selling expenses or its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash generating units).
	The Company is adopting ASU update number 2012-02—Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment whereby the Company will first assess qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, we conclude that it is not more than likely than not that the indefinite-lived intangible asset is impaired, then we are not required to take further action. If the Company concludes otherwise, then we will determine the fair value of the indefinite-lived intangible asset and perform the required quantitative impairment test by comparing the fair value with the carrying amount.
	The Company determined and recorded an impairment loss on goodwill of $405,858 which was included in operating expenses and resulting net operating loss for the year ended December 31, 2012.
Research and Development Expenses	'
	K. Research and Development Expenses
	Under ASC Topic 730 “Research and Development”, costs are expensed as incurred. These expenses include the costs of our proprietary R&D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, any milestone payments will be recorded as Identifiable intangible assets, less accumulated amortization and, unless the asset is determined to have an indefinite life, amortization of the payments will be on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.
Income Taxes	'
	L. Income Taxes
	Under ASC Topic 740, “Income Taxes”, the Company in required to account for its income taxes through the establishment of a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carry forwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for book and tax purposes during the year.
	Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carry forwards. A valuation allowance is established to reduce that deferred tax asset if it is "more likely than not" that the related tax benefits will not be realized.
	Unfiled Federal Tax Returns
	In February 2009, the Company filed appropriate federal tax returns for the years ending December 31, 2003 through 2007 and may be subject to failure to file penalties. For the years ending December 31, 2008 through December 31, 2012, the Company has not filed any federal tax returns. The Company estimates that the amount of penalties, if any, will not have a material effect on the results of operations, cash flows or financial position. No provisions have been made in the financial statements for such penalties, if any.
Marketable Securities	'
	M. Marketable Securities
	Under ASC Topic 210; Rule 5-02.2, ‘‘Marketable Securities’’, the Company is required to measure all marketable securities at their carrying value while recognizing unrealized gains and losses as of the reporting date.
Stock-Based Compensation	'
	N. Stock-Based Compensation
	Under ASC Topic 718, ‘‘Compensation-Stock Compensation’’, the Company is required to measure all employee share-based payments, including grants of employee stock options, using a fair-value-based method and the recording of such expense in the statements of operations. The Company has adopted ASC Topic 718 (SFAS 123R) as of January 1, 2006 and recognizes stock-based compensation expense using the modified prospective method.
Revenue Recognition	'
	O. Revenue Recognition
	Revenue is recognized at the time the educational materials or online seminars are provided and billed to the customer and collection of such fee is reasonably assured. License fees and joint-venture profit sharing when evidenced by executed agreements, and other fees are recognized when earned and collection is reasonably assured.
Basic and Diluted Net Earnings (loss) per Share	'
	P. Basic and Diluted Net Earnings (loss) per Share
	Under ASC Topic 260, "Earnings Per Share" ("EPS"), the Company provides for the calculation of basic and diluted earnings per share. Basic EPS includes no dilution and is computed by dividing income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution of securities that could share in the earnings or losses of the entity. For the nine months ended September 30, 2013 and September 30, 2012, basic and diluted loss per share are the same since the calculation of diluted per share amounts would result in an anti-dilutive calculation.
Development Stage Enterprise	'
	Q. Development Stage Enterprise
	The Company is no longer in the development stage. The Company is actively working on formulations for cannabinoid-based drug development, filing INDs, and commencing drug trials for FDA approved medicine. The Company’s businesses of GGECO and CCI acquired during 2012 are continuing and the Company’s other activities under license agreements with Apothecary has completed over a year of active business and development with expanding operations along with associated business of which the Company earned $70,000 in royalty license revenues in Q3 of 2013 and expects increased revenues in Q4 of 2013. The Company’s MOU with Prescription Vending Machines is progressing with new consultants engaged in Q4 of 2013 to work towards commencing operations in Canada. Therefore, the Company has transitioned out of the development stage as defined under the provisions of ASC Topic 915-10 in the quarter ended September 30, 2013.
Recent Accounting Pronouncements	'
	R. Recent Accounting Pronouncements
	During the nine months ended September 30, 2013 and through November 18, 2013, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.
Reclassifications	'
	S. Reclassifications
	For comparative purposes, certain prior period consolidated financial statements have been reclassified to conform with report classifications of the current year.

Recovered_Sheet2

Fair Value Measurements And Disclosures (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements And Disclosures Tables	'
Schedule Of company's Assets At Fair Value	'
	The following tables set forth by level, within the fair value hierarchy, the Company’s liabilities at fair value as of September 30, 2013.
	31-Dec-12
		Level 1		Level 2		Level 3		Total
	Investment in trading securities	$	525,000	$	—	$	—	$	525,000
	Intangibles from acquisitions, GGECO and CCI
	net of accumulated amortization		—		—		157,918		157,918
	Total assets as of December 31, 2012	$	525,000	$	—	$	157,918	$	682,918
	30-Sep-13
			Level 1		Level 2		Level 3		Total
	Investment in trading securities	$	204,000	$	—	$	—	$	204,000
	Intangibles from GGECO and CCI acquisitions,
	net of accumulated amortization		—		—		237,480		237,480
	Total assets as of September 30, 2013	$	204,000	$	—	$	237,480	$	441,480

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2013
Related Party Transactions Tables	'
Schedule Of Stock Based Compensation With Related Party	'
	For the nine months ended September 30, 2013, the following related party stock-based compensation was recorded:
	Related Party		Position	Amount
	Dr. Dorothy Bray		CEO	$	42,311
	Dr. Robert Malemede		President, CFO		207,186
	Dr. Richard Ogden		CSO		59,415
	Bogat Family Trust1		Managing Consultant		25,000
	Raymond Dabney		Managing Consultant		207,186
	Chad S. Johnson, Esq.		COO and General Counsel		367,500
	Mario Lap		Director		25,525
				$	934,123
Schedule Of Loans Received From Stockholders	'
	During the nine months ended September 30, 2013, a stockholder of the Company, Intrinsic Venture Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Note Amount			Issue Date
	$	20,000		January 2, 2013 (non-cash)
	$	5,000		4-Jan-13
	$	15,000		16-Jan-13
	$	22,000		4-Feb-13
	$	11,000		7-Feb-13
	$	25,000		28-Feb-13
	$	20,000		8-Mar-13
	$	30,500		1-Apr-13
	$	2,500		17-May-13
	$	2,500		30-Aug-13
	$	22,000		13-Sep-13
	During the nine months ended September 30, 2013, a stockholder of the Company, Intrinsic Capital Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Note Amount			Issue Date
	$	22,000		17-May-13
	$	15,000		31-May-13
	$	10,229		3-Jul-13
	$	38,328		23-Jul-13
	$	1,250		15-Aug-13
	$	1,250		30-Aug-13
	$	10,000		9-Sep-13
	$	14,000		11-Sep-13
	$	1,250		30-Sep-13

Equity_Transactions_Tables

Equity Transactions (Tables)	9 Months Ended
	Sep. 30, 2013
Equity Transactions Tables	'
Schedule Of Stock Options Outstanding	'
	A summary of the status of the Company’s option grants as of September 30, 2013 and the changes during the period then ended is presented below:
				Shares		Weighted-Average
						Exercise Price
		Outstanding December 31, 2012			1,700,000	$	0.41
		Granted			—		—
		Exercised			—		—
		Expired			—		—
		Outstanding September 30, 2013			1,700,000	$	0.41
		Options exercisable at September 30, 2013			—		—
Schedule Of Fair Value Assumptions Of Stock Options	'
	The weighted average fair value at date of grant for options during nine months ended September 30, 2013 was estimated using the Black-Scholes option valuation model with the following:
	Average expected life in years		2
	Average risk-free interest rate		2	%
	Average volatility		75	%
	Dividend yield		0	%

Equipment_Tables

Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Equipment Tables	'
Schedule Of Equipment	'
				Accumulated		Net Book Value		Net Book Value
		Cost		Depreciation		30-Sep-13		31-Dec-12
	Equipment	$	3,000	$	3,000	$	—	$	367
	Laboratory equipment		—		—		—		8,895
	Software		5,000		2,859		2,141		4,017
	Computers		5,716		4,933		783		3,133
			13,716		10,792		2,924		16,412

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Intangible Assets Tables	'
Schedule Of Intangible Assets	'
		30-Sep-13			31-Dec-12
	Intellectual assets, primarily intellectual property	$	445,299		$	320,299
	Less accumulated amortization		(217,447	)		(133,761	)
		$	227,852		$	186,538

Subsequent_Events_Tables

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2013
Subsequent Events Tables	'
Schedule Of Loans Received From Stockholders	'
	On Intrinsic Venture Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Amount	Date
	$2,500	1-Oct-13
	$1,275	16-Oct-13
	Intrinsic Capital Corp., loaned the following amounts to the Company that were secured by promissory notes, as follows:
	Amount	Date
	$2,500	1-Oct-13
	$2,750	22-Oct-13
Schedule Of Common Shares Reconciliation	'
	Common shares reconciliation table:
	Issued and outstanding as of September 30, 2013…	710,823,906
	Pending and subsequent event issuances…	50,500,000
	Unissued and outstanding as of November 18, 2013…	761,323,906

Fair_Value_Measurements_And_Di1

Fair Value Measurements And Disclosures (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	$204,000	$525,000
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	237,480	157,918
Total assets	441,480	682,918
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	204,000	525,000
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	'	'
Total assets	204,000	525,000
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	'	'
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	'	'
Total assets	'	'
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in trading securities	204,000	'
Intangibles from acquisitions, GGECO and CCI net of accumulated amortization	237,480	157,918
Total assets	$441,480	$157,918

Related_Party_Transactions_Sch

Related Party Transactions (Schedule Of Stock Based Compensation With Related Party) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Stock based compensation expense	$934,123
Dr.Dorothy Bray	'
Stock based compensation expense	42,311
Dr.Robert Malemede	'
Stock based compensation expense	207,186
Dr.Richard Ogden	'
Stock based compensation expense	59,415
Bogat Family Trust	'
Stock based compensation expense	25,000
Raymond Dabney	'
Stock based compensation expense	207,186
Chad S.Johnson, Esq.	'
Stock based compensation expense	367,500
Mario Lap	'
Stock based compensation expense	$25,525

Related_Party_Transactions_Sch1

Related Party Transactions (Schedule Of Loans Received From Stockholders) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Intrinsic Venture Corp.	'
Debt Instrument [Line Items]	'
Debt instrument face amount	$175,500
Intrinsic Venture Corp. | Notes Payable - January 2, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	20,000
Debt instrument issue date	2-Jan-13
Intrinsic Venture Corp. | Notes Payable - January 4, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	5,000
Debt instrument issue date	4-Jan-13
Intrinsic Venture Corp. | Notes Payable - January 16, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	15,000
Debt instrument issue date	16-Jan-13
Intrinsic Venture Corp. | Notes Payable - February 4, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	22,000
Debt instrument issue date	4-Feb-13
Intrinsic Venture Corp. | Notes Payable - February 7, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	11,000
Debt instrument issue date	7-Feb-13
Intrinsic Venture Corp. | Notes Payable - February 28, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	25,000
Debt instrument issue date	28-Feb-13
Intrinsic Venture Corp. | Notes Payable - March 8, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	20,000
Debt instrument issue date	8-Mar-13
Intrinsic Venture Corp. | Notes Payable - April 1, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	30,500
Debt instrument issue date	1-Apr-13
Intrinsic Venture Corp. | Notes Payable - May 17, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	2,500
Debt instrument issue date	17-May-13
Intrinsic Venture Corp. | Notes Payable - August 30, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	2,500
Debt instrument issue date	30-Aug-13
Intrinsic Venture Corp. | Notes Payable - September 13, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	22,000
Debt instrument issue date	30-Sep-13
Intrinsic Capital Corp.	'
Debt Instrument [Line Items]	'
Debt instrument face amount	113,308
Intrinsic Capital Corp. | Notes Payable - May 17, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	22,000
Debt instrument issue date	17-May-13
Intrinsic Capital Corp. | Notes Payable - May 31, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	15,000
Debt instrument issue date	31-May-13
Intrinsic Capital Corp. | Notes Payable - July 3, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	10,229
Debt instrument issue date	3-Jul-13
Intrinsic Capital Corp. | Notes Payable - July 23, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	38,328
Debt instrument issue date	23-Jul-13
Intrinsic Capital Corp. | Notes Payable - August 15, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	1,250
Debt instrument issue date	15-Aug-13
Intrinsic Capital Corp. | Notes Payable - August 30, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	1,250
Debt instrument issue date	30-Aug-13
Intrinsic Capital Corp. | Notes Payable - September 9, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	10,000
Debt instrument issue date	9-Sep-13
Intrinsic Capital Corp. | Notes Payable - September 11, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	14,000
Debt instrument issue date	11-Sep-13
Intrinsic Capital Corp. | Notes Payable - September 30, 2013	'
Debt Instrument [Line Items]	'
Debt instrument face amount	$1,250
Debt instrument issue date	30-Sep-13

Equity_Transactions_Schedule_O

Equity Transactions (Schedule Of Stock Options Outstanding) (Details) (Stock Options, USD $)	9 Months Ended
	Sep. 30, 2013
Stock Options	'
Shares	'
Outstanding December 31, 2012	1,700,000
Granted	'
Exercised	'
Expired	'
Outstanding September 30, 2013	1,700,000
Options exercisable at September 30, 2013	'
Weighted Average Exercise Price	'
Balance at March 31, 2013	$0.41
Granted	'
Exercised	'
Expired	'
Balance outstanding at June 30, 2013	$0.41
Options exercisable at end of year	'

Equity_Transactions_Schedule_O1

Equity Transactions (Schedule Of Fair Value Assumptions Of Stock Options) (Details) (Stock Options)	9 Months Ended
	Sep. 30, 2013
Stock Options	'
Fair value of Stock Options - Black Scholes Options Valuation Model	'
Average expected life in years	'2 years
Average risk-free interest rate	2.00%
Average volatility	75.00%
Dividend yield	0.00%

Equipment_Details

Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Cost	$13,716	'
Accumulated depreciation	10,792	7,327
Net book value	2,924	16,412
Equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	3,000	'
Accumulated depreciation	3,000	'
Net book value	'	367
Laboratory Equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	'	'
Accumulated depreciation	'	'
Net book value	'	8,895
Software	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	5,000	'
Accumulated depreciation	2,859	'
Net book value	2,141	4,017
Computers	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	5,716	'
Accumulated depreciation	4,933	'
Net book value	$783	$3,133

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Intangible Assets Details	'	'
Intellectual assets, primarily intellectual property	$445,299	$320,299
Less accumulated amortization	217,447	133,761
Intangible assets, net	$227,852	$186,538

Subsequent_Events_Schedule_Of_

Subsequent Events (Schedule Of Loans Received From Stockholders) (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2013	Nov. 18, 2013	Nov. 18, 2013	Nov. 18, 2013	Nov. 18, 2013	Nov. 18, 2013
	Intrinsic Venture Corp.	Intrinsic Capital Corp.	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event	Subsequent Event
				Intrinsic Venture Corp.	Intrinsic Venture Corp.	Intrinsic Capital Corp.	Intrinsic Capital Corp.
				Notes Payable - October 1, 2013	Notes Payable - October 16, 2013	Notes Payable - October 1, 2013	Notes Payable - October 22, 2013
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Debt instrument face amount	$175,500	$113,308	$9,025	$2,500	$1,275	$2,500	$2,750
Debt instrument issue date	'	'	'	1-Oct-13	16-Oct-13	1-Oct-13	22-Oct-13

Subsequent_Events_Schedule_Of_1

Subsequent Events (Schedule Of Common Shares Reconciliation) (Details)	Sep. 30, 2013	Dec. 31, 2012	Nov. 18, 2013
			Common Stock
			Subsequent Event
Balance shares	710,823,906	663,790,573	710,823,906
Pending and subsequent event issuances	'	'	50,500,000
Unissued and outstanding balance	'	'	761,323,906

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013	Feb. 09, 2012	Feb. 09, 2012	Feb. 09, 2012	Feb. 09, 2012	Mar. 21, 2012
				GGECO University, Inc	GGECO University, Inc	GGECO University, Inc	GGECO University, Inc	GGECO University, Inc	Cannabis Consulting, Inc
						Education Materials	Trade Name	Workforce
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'
Business acquisition purchase price	'	'	'	'	$450,132	'	'	'	'
Value of intangibles acquired	'	'	'	'	192,119	150,000	20,000	22,119	125,000
Value of goodwiil	66,274	'	44,274	44,274	'	'	'	'	22,000
Impairment loss on goodwill	$8,896	'	$405,858	'	'	'	'	'	'

Marketable_Securities_Narrativ

Marketable Securities (Narrative) (Details) (Endocan Corporation, USD $)	0 Months Ended		9 Months Ended
	Feb. 08, 2013	Dec. 12, 2012	Sep. 30, 2013
Endocan Corporation	'	'	'
Equity method investment ownership percentage	'	'	8.60%
Common stock issued in connection with joint ventures, Shares	2,500,000	5,000,000	7,500,000
Fair market value of shares acquired	$262,250	$150,000	$204,000
Fair market value per share of shares acquired	$0.10	$0.03	$0.03

Related_Party_Transactions_Nar

Related Party Transactions (Narrative) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Jan. 02, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012	Jan. 02, 2013
			Bogat Family Trust	Bogat Family Trust	Bogat Family Trust	Raymond Dabney	Raymond Dabney	Dr.Robert Malemede
			Series A Preferred Shares	Loans Payable	Loans Payable	Loans Payable	Loans Payable	Series A Preferred Shares
Advances from related parties	$239,344	$196,703	'	$233,178	$196,703	$6,166	$0	'
Stock issued for services, shares	'	'	166,667	'	'	'	'	166,667

Notes_Payable_Narrative_Detail

Notes Payable (Narrative) (Details)	9 Months Ended
	Sep. 30, 2013
Notes Payable Narrative Details	'
Debt instrument description	'
	As at September 30, 2013, a total of $1,539,502 (December 31, 2012: $1,307,218) of notes payable are due to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on October 1, 2013 through September 30, 2014.

Equity_Transactions_Narrative_

Equity Transactions (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Jun. 07, 2013

Jul. 26, 2013

Feb. 28, 2013

Sep. 26, 2013

Aug. 26, 2013

Jul. 26, 2013

Jul. 02, 2013

26-May-13

Mar. 26, 2013

Jun. 24, 2013

20-May-13

Apr. 12, 2013

Apr. 26, 2013

Mar. 28, 2013

Mar. 07, 2013

Feb. 11, 2013

Jan. 29, 2013

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Private Placement

Note payable debt

Note payable debt

Dr Richard Ogden, CSO

Dr Richard Ogden, CSO

Dr Richard Ogden, CSO

Dr Richard Ogden, CSO

Dr Richard Ogden, CSO

Dr Richard Ogden, CSO

Mario Lap

Dr Mohammad Afaneh

Dr Mohammad Afaneh

Saientific Advisor

Saientific Advisor

Saientific Advisor

Saientific Advisor

Chad S. Johnson, Esq, COO

Shares issued for services

'

'

'

'

'

17,700,000

171,669,999

'

'

'

100,000

100,000

100,000

100,000

100,000

100,000

5,000,000

5,000,000

'

100,000

500,000

500,000

1,000,000

5,000,000

Fair market valueof share

'

'

'

'

'

'

'

$0.06

'

'

$0.05

$0.04

$0.04

$0.04

$0.06

$0.08

'

'

'

$0.07

$0.72

$0.07

$0.07

'

Shares issued for debt settlement

'

'

'

'

'

28,500,000

155,700,000

'

15,000,000

13,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt settlement amount

'

'

$28,500

$148,200

'

'

'

'

$15,000

$13,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on settlement

-582,000

-1,530,000

-1,674,150

-10,826,800

'

'

'

'

582,000

1,092,150

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value issued for services

'

'

397,850

'

1,147,425

17,700

171,670

'

'

'

'

'

'

'

'

'

185,000

230,500

'

'

38,750

35,750

71,500

250,000

Shares issued for private placement

'

'

'

'

'

'

7,000,000

833,333

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share value of private placement

'

'

'

'

$338,800

'

$7,000

$25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares cancelled

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,750,000

'

'

'

'

'

Equipment_Narrative_Details

Equipment (Narrative) (Details)	9 Months Ended
	Sep. 30, 2013
Computer	'
Useful life of Equipment	'2 years
Software	'
Useful life of Equipment	'2 years
Equipment	'
Useful life of Equipment	'5 years
Laboratory Equipment	'
Useful life of Equipment	'5 years

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (Intangible Assets)	9 Months Ended
	Sep. 30, 2013
Intangible Assets	'
Useful life of Intangible	'5 years

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Nov. 18, 2013

Nov. 05, 2013

Nov. 06, 2013

Nov. 05, 2013

Nov. 05, 2013

Nov. 18, 2013

Oct. 21, 2013

Oct. 21, 2013

Oct. 21, 2013

Nov. 18, 2013

Common Stock

Common Stock

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Subsequent Event

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Dr.Dorothy Bray

Mario Lap

Chad S.Johnson, Esq.

Robert Kane

Consultant For Business Development Services

Consultant For Business Development Services

Consultant For Research and Development Services

Common Stock

Common Stock

Common Stock

Total promissory note loans

'

'

'

'

'

'

'

$9,025

'

'

'

'

'

'

'

'

'

Common stock issued for services, Shares

'

'

'

'

'

17,700,000

171,669,999

'

'

'

5,000,000

5,000,000

1,000,000

5,000,000

5,000,000

5,000,000

1,500,000

Common stock issued for services, Amount

'

'

397,850

'

1,147,425

17,700

171,670

'

'

'

170,000

170,000

37,000

190,000

190,000

190,000

52,500

Common stock issued for debt settlements, Shares

'

'

'

'

'

28,500,000

155,700,000

'

9,000,000

9,000,000

'

'

'

'

'

'

'

Common stock issued for debt settlements, Amount

'

'

1,702,650

'

10,843,800

28,500

155,700

'

9,000

9,000

'

'

'

'

'

'

'

Sale of stock price per share

'

'

'

'

'

'

'

'

'

'

$0.03

$0.03

$0.04

$0.03

$0.03

$0.03

$0.03

Loss on settlement of debt

($582,000)

($1,530,000)

($1,674,150)

($10,826,800)

'

'

'

'

($297,000)

($283,500)

'

'

'

'

'

'

'